Questions About Cancer? 1-800-4-CANCER

Chronic Lymphocytic Leukemia Treatment (PDQ®)

Health Professional Version
Last Modified: 04/19/2013

Changes to This Summary (04/19/2013)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Stage I, II, III, and IV Chronic Lymphocytic Leukemia

Revised text to state that the surrogate endpoint of such clearance of residual disease, while prognostic, has not been shown to improve survival in a randomized prospective trial.

Revised text in the third treatment option to state that a trial of 138 patients, who were previously treated with fludarabine and alemtuzumab, showed overall response rates around 50% in patients refractory to fludarabine and with prior exposure to rituximab (cited Wierda et al. as reference 14).

Added text to include lenalidomide as a treatment option and stated that it is an oral immunomodulatory agent with response rates over 50% for patients with previously treated and untreated disease (cited Chen et al., Chanan-Khan et al., and Ferrajoli et al. as references 34, 35, and 36, respectively, and Badoux et al. as reference 37 and level of evidence 3iiiDiv). Also added that prolonged, lower-dose approaches and attention to prevention of tumor lysis syndrome are recommended with this agent (cited Moutouh-de Parseval et al. as reference 38). Combination therapy and long-term toxicities from using lenalidomide remain undefined for patients with chronic lymphocytic leukemia.

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.